Maria Elisa R. M.
- Country
- Spain
- Department
- Hepathology
Research Overview
- Evaluation of Efficacy and Safety of TheraSphere Followed by Durvalumab and Tremelimumab in Hepatocellular Carcinoma Patients
- Phase III Randomized Study of Durvalumab and Tremelimumab Versus Sorafenib in First-Line Treatment of Unresectable Advanced Hepatocellular Carcinoma
- Phase 1/2 Open-Label Study of CTL-002 and Nivolumab in Advanced Relapsed/Refractory Solid Tumors
Data & Insights
Has run more than one trial at 82 of 194 partner sites.
Specializations
Liver Cancer Expertise
The investigator specializes in treating advanced hepatocellular carcinoma and exploring innovative therapeutic approaches for patients with liver malignancies. Their research encompasses both resectable and unresectable HCC, with particular attention to cases requiring systemic treatment.
- Advanced-stage liver cancer management
- Locoregional treatment approaches
- Intermediate-stage HCC interventions
Immunotherapy Applications
Focuses on developing and evaluating immunomodulatory treatments for hepatobiliary cancers. The investigator works with various immune checkpoint inhibitors and their combinations, including novel therapeutic approaches for patients who have not responded to conventional treatments.
- Combination immunotherapy strategies
- First-line immunotherapy protocols
- Treatment-resistant cases
Multi-Modal Treatment Approaches
Investigates integrated treatment strategies combining targeted therapies with immunological agents. Their work includes evaluation of novel combinations incorporating transarterial chemoembolization and radiation therapy with immunotherapy.
- Combined therapeutic modalities
- Innovative treatment sequences
- Advanced intervention protocols
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.